The United States will allow baby formula imports from foreign makers that do not usually sell their products here, the Food and Drug Administration said on May 16, as it tries to ease a nationwide shortage that has left parents scrambling to feed their babies.
As the fairness of orphan drug exclusivities is debated in Congress, the U.S. Food and Drug Administration granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
The White House is preparing for a scenario in which Congress fails to approve President Joe Biden’s request for additional COVID funds by reviewing old contracts to see if there is any money it can “claw back,” the president’s top COVID adviser said on May 12.
U.S. will share COVID-19 vaccine technology, Biden tells global summit
Antivirals, BNT162b2 (Pfizer and BioNTech), Congress, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 Vaccines, Janssen COVID-19 Vaccine (J&J), Joe Biden, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Pandemic Preparedness, Pandemics, Summits, Therapeutics, U.S. government, United States, Vaxzevria (previously COVID-19 Vaccine AstraZeneca), WHO, World Bank, World Health OrganizationThe United States will share technologies used to make COVID-19 vaccines through the World Health Organization and is working to expand rapid testing and antiviral treatments for hard-to-reach populations, President Joe Biden said on May 12.
Biden marks 1 million Americans dead from COVID
Congress, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19), Coronavirus Infections, Coronavirus Mutations, Coronavirus Restrictions, Coronavirus surge, COVID-19 booster shots, COVID-19 Deaths, COVID-19 Infections, COVID-19 shots, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 treatment pill, COVID-19 vaccination rates, Covid-19 Variants, Joe Biden, Pandemics, Reuters Tally, SARS-CoV-2 virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Summits, United States, White House, White House coronavirus task forcePresident Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.
The United States on April 13 renewed the COVID-19 public health emergency, allowing millions of Americans to keep getting free tests, vaccines and treatments for at least three more months.
U.S. Congress Proposes Bills to Strengthen Pharma Competition, Promote Innovation
Authorized Generics, Biosimilars, Branded Generics, Clinical Trials, Congress, Drug Price Reform, Drug Prices, Drug Pricing, Generic Substitution, Generics, House Committee on Oversight and Government Reform, Interchangeable Biosimilars, Pricing, R&D, R&D Investment ReturnOn Thursday, members of both the U.S. House of Representatives and the U.S. Senate introduced legislation that targets efforts that have limited competition, which keeps the price of prescription drugs high.
Accelerated Approval Integrity Act Could Remove Therapies Before They Prove Merit
Accelerated Approval Integrity Act of 2022 (H.R. 6963), Alzheimer's Disease, Bills, Clinical Trials, Congress, FDA, Hearings, House Committee on Energy and Commerce, House of Representatives, Legislation, Neurodegenerative Diseases, R&D, TherapeuticsThe Accelerated Approval Integrity Act of 2022 (H.R. 6963) aims to remove loopholes in the Food and Drug Administration’s accelerated approval pathway. The bill, however, fails to adequately consider the whole picture, and may inadvertently remove medications that simply can’t complete confirmatory trials within the narrow timeframe allowed.
Negotiators in Congress agreed to an additional $10 billion in COVID-19 funding to address U.S. needs but have dropped international aid from the package, Senate Majority Leader Chuck Schumer said on April 4.
The high cost of insulin to treat diabetes would be drastically reduced under legislation the U.S. House of Representatives passed on March 31, in a rare example of drug price reform gaining traction in Congress.